… Hepatic failure and hepatorenal syndrome, including fatal cases, can occur with erlotinib
treatment in patients with normal hepatic function; the risk of hepatic toxicity is increased in …

… Patients in the EGFR-TKIs group received treatment with erlotinib hydrochloride, afatinib
dimaleate, or gefitinib at standard dosage according to physician preference. Patients in the …

… endothelial growth factor (VEGF) and epidermal growth factor … Epidermal growth factor
receptor (EGFR) mutation-positive … Erlotinib (ERL), one of EGFR tyrosine kinase inhibitors (TKIs)…

… treatment with epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), …
bevacizumab plus erlotinib significantly prolonged progression-free survival compared with …

… Patients with advanced NSCLC who were treated with oral erlotinib at a standard dose of …
; 2) unmodified dosage of erlotinib during the treatment period. This study was designed and …

… RAM + ERL offers a tolerable and effective option for the first-line treatment of epidermal
growth factor receptor exon 19 deletion or exon 21 (L858R) mutation-positive metastatic non-…

… growth factor receptor (EGFR) have been evaluated in patients with advanced non-small cell
lung cancer (NSCLC). Erlotinib … patients taking erlotinib and gefitinib for treating NSCLC in …

… erlotinib treatment [34]. In the previous three clinical studies (JO25567, NEJ026, and RELAY
trials), only a few patients had plasma ctDNA for EGFR-T790M mutation tests (NEJ026), but …

… cancer treatments for a subtype known as non-small cell lung cancer with a special mutation
of epidermal growth factor … therapy with erlotinib, and in 36 patients who concluded erlotinib …

… Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an …
with erlotinib and cetuximab. We also evaluated the anti-tumor efficacy of this treatment per …